U.S. Markets close in 5 hrs 40 mins

CTI BioPharma Has Fallen Almost 39% Today

Margaret Patrick
CTI BioPharma Has Fallen Almost 39% Today

Why Is CTI BioPharma Stock Down Today? On July 18, CTI BioPharma (CTIC) announced the outcome of its type B meeting with the FDA related to its investigational drug pacritinib. As per the FDA’s feedback, the company now needs to conduct a Phase 3 trial to evaluate this second-generation JAK2 inhibitor for the treatment of myelofibrosis patients suffering from thrombocytopenia or who have already been treated with ruxolitinib.